A review in JAMA Otolaryngology–Head & Neck Surgery has pulled together what is known about GLP-1 drugs and obstructive sleep apnea, and its bottom line is a qualified one: the drugs work, and they work less well than CPAP. Across six meta-analyses the reduction in the apnea-hypopnea index ran from 5.7 to 21.9 events per … Read more
A network meta-analysis published in Endocrinology, Diabetes & Metabolism pooled 43 studies covering 932,380 patients and compared bariatric surgery against GLP-1 receptor agonists on hard cardiovascular outcomes. Surgery was associated with reductions in major adverse cardiovascular events, heart failure and myocardial infarction. The drugs were associated with a reduction in major adverse cardiovascular events but … Read more
A research brief published in Pediatrics on 4 September finds that GLP-1 prescribing to children aged 8 to 11 with obesity rose steeply between 2019 and 2026 while remaining uncommon: across 3,520,531 children in the dataset, 0.6% received a prescription. Every one of those prescriptions was off-label. The three drugs counted are labelled from age … Read more
A study of 63,215 patients with pre-existing neuropsychiatric conditions, published on 1 September, found semaglutide associated with broadly lower rates of neuropsychiatric events over two years than metformin, SGLT2 inhibitors or DPP-4 inhibitors. Within the semaglutide group, patients who reached higher doses had fewer such events afterwards — the inverse of the dose-toxicity pattern implied … Read more
Eli Lilly announced 52-week results on 31 August 2026 from two Phase 3b trials testing whether adding tirzepatide (Zepbound) to the psoriasis biologic ixekizumab (Taltz) works better than the biologic alone in adults who have psoriatic disease and obesity. It did, on both trials’ primary outcomes and by wide margins. But the primary outcomes were … Read more
A meta-analysis published in Endocrinology, Diabetes & Metabolism in September 2026 puts a number on something patients ask about far more often than they are answered: what happens after you stop. Pooling six studies and 1,776 participants, it estimates weight comes back at 1.04 kg per month, that half of everything lost is back within … Read more
An updated systematic review published in Annals of Internal Medicine on 1 September 2026 pooled 38 randomised trials covering 25,816 adults who had overweight or obesity but not diabetes. It is the cleanest single answer yet to the question most readers arrive with: how much weight does each of these drugs actually take off, above … Read more
A Barcelona hospital followed 83 adults with obesity through a year of routine care and measured what most weight-loss studies only estimate: fat, lean tissue, resting energy expenditure and handgrip strength. The 44 patients on semaglutide lost substantially more weight than the 39 on a lifestyle programme alone. They also lost lean tissue — about … Read more